Aerium

Aerium Therapeutics SA is dedicated to the discovery and development of antibodies and small-molecule antiviral drugs against the novel coronavirus and other epidemic-causing viruses. The company's primary asset is a monoclonal antibody targeting the novel coronavirus, which has demonstrated potent neutralizing activity in laboratory tests against all relevant variants discovered to date, including Delta and Omicron. High-resolution structural characterization of the antibody reveals non-overlapping epitopes and a synergistic mechanism of action, making it a potential candidate for the treatment or prevention of COVID-19 and its variants from currently circulating strains of the novel coronavirus. The company’s fully integrated discovery platform leverages an extensive network of international collaborations and established research infrastructures of leading European institutions. Its capabilities include BSL-3/P3 laboratories for advanced viral testing, Cryo-EM expertise for rapid viral protein characterization, and an antibody discovery platform that has already generated Aerium's promising lead monoclonal antibody.